-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2025-522231-34-00
5
2026-03-31
Diabetic Macular Edema
-
2025-522578-35-00
4
2026-03-30
Atopic Dermatitis
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2025-522232-13-00
4
2026-03-06
Sepsis-associated acute kidney injury (AKI)
-
2025-521742-15-00
4
2026-03-03
Treatment of Late Isolated Microvascular Inflammation in Recipients of
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-522015-42-00
10
2026-02-26
Chronic Hepatitis D Infection
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-523706-32-00
3
2026-02-17
not applicable (submitted trial is a pharmacokinetic study in healthy
-
2024-516966-12-00
4
2026-02-13
Alzheimer’s disease
-
2025-522514-23-00
5
2026-02-12
Urinary Incontinence
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-522370-36-00
4
2026-02-02
Moderate to Severe Atopic Dermatitis
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521606-18-00
4
2026-01-29
Ovarian Cancer
-
2025-520688-42-00
4
2026-01-27
Amyotrophic Lateral Sclerosis (ALS)
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2025-522333-61-00
4
2026-01-23
Hidradenitis suppurativa
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma